ViraTherapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 41

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $243M

ViraTherapeutics General Information

Description

Developer of next-generation oncolytic viral therapy platform created for the treatment of cancer. The company develops highly potent anti-cancer therapeutics based on oncolytic viruses that efficiently destroy cancer cells while leaving normal tissues unharmed and also develops oncolytic cancer vaccines based on a chimeric virus derived from the vesicular stomatitis virus.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Boehringer Ingelheim
Corporate Office
  • Bundesstraße 27
  • Rum, 6063
  • Austria
+43 0512 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ViraTherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 13-Sep-2018 $243M 00.000 00000 Completed Generating Revenue
6. Early Stage VC (Series B) 28-Oct-2016 00.000 00.000 Completed Generating Revenue
5. Early Stage VC (Series A) 24-Jun-2015 00.000 00.000 Completed Startup
4. Grant 01-Dec-2014 00.000 Completed Startup
3. Grant 01-Jul-2013 000.00 Completed Startup
2. Angel (individual) 01-Apr-2013 Completed Startup
1. Spin-Off 01-Apr-2013 Completed Startup
To view ViraTherapeutics’s complete valuation and funding history, request access »

ViraTherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of next-generation oncolytic viral therapy platform created for the treatment of cancer. The company develops
Drug Discovery
Rum, Austria
41 As of 2023
00.000
00000 0000-00-00
000000&0 00.000

000000

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000000000000
Rochester, MN
00 As of 0000
00000
00000 0000-00-00
00000000000 00000

000000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
0000 000000000
Philadelphia, PA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViraTherapeutics Competitors (117)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vyriad Venture Capital-Backed Rochester, MN 00 00000 00000000000 00000
Carisma Therapeutics Formerly VC-backed Philadelphia, PA 00 00000 000000000 00000
Circio Formerly VC-backed Lysaker, Norway 00 00000 000000000 00000
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
Adicet Bio Formerly VC-backed Boston, MA 000 00000 00000000 00000
You’re viewing 5 of 117 competitors. Get the full list »

ViraTherapeutics Patents

ViraTherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230183650-A1 Vsv rescue Pending 09-Jul-2021 00000000
US-20220088162-A1 Heterologous prime boost vaccine Pending 14-Sep-2020 00000000000
US-20220010286-A1 Process for producing a purified rhabdovirus from cell culture Pending 10-Jul-2020 00000000
US-20210379130-A1 Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein Pending 03-Jun-2020 0000000000 0
US-20220228172-A1 Novel mechanism to control rna virus replication and gene expression Pending 21-Jun-2019 C12N7/00
To view ViraTherapeutics’s complete patent history, request access »

ViraTherapeutics Executive Team (4)

Name Title Board Seat Contact Info
Ludwig Weiss Ph.D Co-Founder, Chief Executive Officer & Chief Financial Officer
Lisa Egerer Ph.D Chief Operating Officer
Dorothee Holm-von Laer Co-Founder & Scientific Advisor
Heinz Schwer Ph.D Chief Executive Officer
To view ViraTherapeutics’s complete executive team members history, request access »

ViraTherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViraTherapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Austria Wirtschaftsservice Venture Capital Minority 000 0000 000000 0
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
EMBL Ventures Venture Capital Minority 000 0000 000000 0
EMPL Fahrzeugwerk Corporation Minority 000 0000 000000 0
Research Studio Austria Corporation 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

ViraTherapeutics FAQs

  • When was ViraTherapeutics founded?

    ViraTherapeutics was founded in 2013.

  • Who is the founder of ViraTherapeutics?

    Ludwig Weiss Ph.D and Dorothee Holm-von Laer are the founders of ViraTherapeutics.

  • Who is the CEO of ViraTherapeutics?

    Ludwig Weiss Ph.D and Heinz Schwer Ph.D are the CEOs of ViraTherapeutics.

  • Where is ViraTherapeutics headquartered?

    ViraTherapeutics is headquartered in Rum, Austria.

  • What is the size of ViraTherapeutics?

    ViraTherapeutics has 41 total employees.

  • What industry is ViraTherapeutics in?

    ViraTherapeutics’s primary industry is Drug Discovery.

  • Is ViraTherapeutics a private or public company?

    ViraTherapeutics is a Private company.

  • What is the current valuation of ViraTherapeutics?

    The current valuation of ViraTherapeutics is 00000.

  • What is ViraTherapeutics’s current revenue?

    The current revenue for ViraTherapeutics is 000000.

  • How much funding has ViraTherapeutics raised over time?

    ViraTherapeutics has raised $8.55M.

  • Who are ViraTherapeutics’s investors?

    Austria Wirtschaftsservice, Boehringer Ingelheim Venture Fund, EMBL Ventures, EMPL Fahrzeugwerk, and Research Studio Austria are 5 of 8 investors who have invested in ViraTherapeutics.

  • Who are ViraTherapeutics’s competitors?

    Vyriad, Carisma Therapeutics, Circio, Kite Pharma, and Adicet Bio are some of the 117 competitors of ViraTherapeutics.

  • When was ViraTherapeutics acquired?

    ViraTherapeutics was acquired on 13-Sep-2018.

  • Who acquired ViraTherapeutics?

    ViraTherapeutics was acquired by Boehringer Ingelheim.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »